High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD)

Recruiting

I'm Interested

Trial ID: NCT05587673

Age - 4 Years-25 Years Gender - All Accepting Healthy Volunteers - No

Purpose

This study will examine whether delivery of high dose steroids, directly into the inflamed bowel via its arterial blood supply, will be better for treating uncontrolled flares of inflammatory bowel disease in patients compared to conventional intra-venous or oral administration of this drug. Patients aged 4-25 years of age will be recruited. In this study, we hope to also learn how this directed steroid delivery during an active flare will improve patient symptoms as well as the appearance of inflamed segments of bowel determined by imaging or biopsy (i.e. at the time of endoscopy). Additional data will determine how the blood vessels in the bowel affect, and potentially even drive the mechanisms, of inflammatory bowel disease.

Official Title

A Pilot Study Investigating the Feasibility and Efficacy of Locoregional Intra-arterial Administration of Methylprednisolone as a Bridge Therapy to Treat Symptomatic Flares in Inflammatory Bowel Disease.

Stanford Investigator(s)

Avnesh Thakor
Avnesh Thakor

Associate Professor of Radiology (Pediatric Radiology)

Eligibility


Inclusion Criteria:

   - Patients with newly diagnosis of inflammatory bowel disease (IBD) or patients who have
   an established diagnosis of IBD and are experiencing an acute flare which is not being
   controlled with first line therapy

   - Patients present with typical IBD symptoms which will include, but are not limited to,
   abdominal pain, loss of appetite, rectal bleeding, diarrhea, obstruction, or passage
   of mucus.

   - Patients referred by the GI team.

   - Patients (or guardians/parents) must be able and willing to give consent (or assent
   where applicable) and be able to attend all study visits.

Exclusion Criteria:

   - Patients with MR unsafe metallic implants that will not be able to undergo the MRI
   portion of the study.

   - Patients with renal function impairment (GFR < 45 mL/min) preventing contrast
   administration.

   - Patients with contrast allergy.

View More
View Less

Intervention(s):

drug: Methylprednisolone

Recruiting

I'm Interested

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Avnesh Thakor, MD
650-736-4747

©2024 Stanford Medicine